January 31, 2015 6:05 PM ET


Company Overview of Dezima Pharma B.V.

Executive Profile

Johannes Jacob Pieter Kastelein M.D., Ph.D., FESC

Co-Principal Investigator and Member of The Medical Advisory Board, AtheroNova Inc.
AgeTotal Calculated CompensationThis person is connected to 12 Board Members in 12 different organizations across 15 different industries.

See Board Relationships


Prof. Johannes Jacob Pieter Kastelein, also known as John, MD, PhD, FESC, is a Co-Founder of uniQure BV. Prof. Kastelein serves as Scientific Advisor of Forbion Capital Partners. He advises Forbion on the cardiovascular and metabolic disease space and presents Forbion with investment opportunities in these fields. He serves as the Medical Director of Dutch National Foundation for the Identification of Familial Hypercholesterolemia, which he founded. Prof. Kastelein is ...

Corporate Headquarters

Gooimeer 2-35
Naarden, Noord-Holland 1411 DC


Phone: 31 35 699 3000
Fax: --

Board Members Memberships



MD 1980
University of Amsterdam

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Dezima Pharma B.V., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.